September 10, 2025Future OncologyOpen Access

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis reveals adherence and treatment duration trends in mantle cell lymphoma patients using BTK inhibitors.

Zanubrutinib group had significantly longer median treatment duration compared to acalabrutinib and ibrutinib.
Patients in the zanubrutinib group demonstrated higher adherence rates to treatment than those on other BTK inhibitors.
The analysis followed patients for at least six months, focusing on treatment patterns of BTK inhibitors.
402 patients initiated treatment with either acalabrutinib, ibrutinib, or zanubrutinib from January 2019 to November 2021.

Shah et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark